ACIU vs. GLPG, ZLAB, KROS, NAMS, HRMY, EVO, PTGX, SNDX, TARO, and EWTX
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Galapagos (GLPG), Zai Lab (ZLAB), Keros Therapeutics (KROS), NewAmsterdam Pharma (NAMS), Harmony Biosciences (HRMY), Evotec (EVO), Protagonist Therapeutics (PTGX), Syndax Pharmaceuticals (SNDX), Taro Pharmaceutical Industries (TARO), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Galapagos received 212 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 64.54% of users gave Galapagos an outperform vote while only 62.25% of users gave AC Immune an outperform vote.
Galapagos currently has a consensus target price of $34.50, indicating a potential upside of 28.92%. AC Immune has a consensus target price of $12.00, indicating a potential upside of 151.57%. Given Galapagos' stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Galapagos.
AC Immune has a net margin of 0.00% compared to AC Immune's net margin of -26.25%. AC Immune's return on equity of -2.60% beat Galapagos' return on equity.
32.5% of Galapagos shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Galapagos had 3 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for Galapagos and 0 mentions for AC Immune. Galapagos' average media sentiment score of 1.18 beat AC Immune's score of -0.31 indicating that AC Immune is being referred to more favorably in the news media.
Galapagos has higher revenue and earnings than AC Immune.
Galapagos has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Summary
AC Immune beats Galapagos on 9 of the 16 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
